Literature DB >> 16264014

Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-alpha blockage.

Andrea Deutschmann1, Christoph J Mache, Koppany Bodo, Doris Zebedin, Ekkehard Ring.   

Abstract

We describe the case of an 18-year-old girl with chronic recurrent multifocal osteomyelitis (CRMO) over a period of 10 years. She had suffered predominantly from very painful recurrent swelling of her cheeks. Various therapeutic regimens including nonsteroidal antiinflammatory drugs and steroids had shown only a partial or temporary response. Because tumor necrosis factor-alpha-blocking agents have been successfully applied in Crohn's-associated CRMO and the related SAPHO (synovitis, acne, pustulosis, hyperostosis, and osteitis) syndrome, tumor necrosis factor-alpha-blocking therapy with infliximab was initiated. Thereafter, apart from 1 mild episode, no additional recurrences were observed during 21 months of follow-up. Infliximab was well tolerated, and steroids were tapered off. Our observation indicates that infliximab may be an effective therapeutic option in CRMO.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16264014     DOI: 10.1542/peds.2004-2206

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  32 in total

1.  Spinal involvement in chronic recurrent multifocal osteomyelitis (CRMO) in childhood and effect of pamidronate.

Authors:  Toni Hospach; Micha Langendoerfer; Tekla von Kalle; Jan Maier; Guenther E Dannecker
Journal:  Eur J Pediatr       Date:  2010-03-27       Impact factor: 3.183

Review 2.  An Update on the Pathogenesis and Treatment of Chronic Recurrent Multifocal Osteomyelitis in Children.

Authors:  Andrea Taddio; Floriana Zennaro; Serena Pastore; Rolando Cimaz
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

Review 3.  Biologic treatment for chronic recurrent multifocal osteomyelitis: report of four cases and review of the literature.

Authors:  Elena Tronconi; Angela Miniaci; Michelangelo Baldazzi; Laura Greco; Andrea Pession
Journal:  Rheumatol Int       Date:  2017-11-11       Impact factor: 2.631

Review 4.  New discoveries in CRMO: IL-1β, the neutrophil, and the microbiome implicated in disease pathogenesis in Pstpip2-deficient mice.

Authors:  Polly J Ferguson; Ronald M Laxer
Journal:  Semin Immunopathol       Date:  2015-04-17       Impact factor: 9.623

Review 5.  The SAPHO syndrome revisited with an emphasis on spinal manifestations.

Authors:  Antonio Leone; Victor N Cassar-Pullicino; Roberto Casale; Nicola Magarelli; Alessia Semprini; Cesare Colosimo
Journal:  Skeletal Radiol       Date:  2014-10-21       Impact factor: 2.199

Review 6.  Chronic recurrent multifocal osteomyelitis involving the mandible: case reports and review of the literature.

Authors:  P A J Monsour; J B Dalton
Journal:  Dentomaxillofac Radiol       Date:  2010-03       Impact factor: 2.419

Review 7.  New insights into synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome.

Authors:  Marina Magrey; Muhammad A Khan
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

8.  Chronic nonbacterial osteomyelitis in a child with previous juvenile dermatomyositis.

Authors:  Daniela S Ardelean; Peter B Dent; Polly J Ferguson; Ronald M Laxer
Journal:  J Rheumatol       Date:  2013-03       Impact factor: 4.666

9.  Chronic nonbacterial osteomyelitis in childhood: prospective follow-up during the first year of anti-inflammatory treatment.

Authors:  Christine Beck; Henner Morbach; Meinrad Beer; Martin Stenzel; Dennis Tappe; Stefan Gattenlöhner; Ulrich Hofmann; Peter Raab; Hermann J Girschick
Journal:  Arthritis Res Ther       Date:  2010       Impact factor: 5.156

10.  Dramatic pain relief and resolution of bone inflammation following pamidronate in 9 pediatric patients with persistent chronic recurrent multifocal osteomyelitis (CRMO).

Authors:  Paivi Mh Miettunen; Xingchang Wei; Deepak Kaura; Walid Abou Reslan; Alberto Nettel Aguirre; James D Kellner
Journal:  Pediatr Rheumatol Online J       Date:  2009-01-12       Impact factor: 3.054

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.